vs
EXACT SCIENCES CORP（EXAS）与先锋自然资源公司（PR）财务数据对比。点击上方公司名可切换其他公司
先锋自然资源公司的季度营收约是EXACT SCIENCES CORP的1.3倍（$1.2B vs $878.4M），先锋自然资源公司净利率更高（29.0% vs -9.8%，领先38.8%），EXACT SCIENCES CORP同比增速更快（23.1% vs -9.8%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -3.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
先锋自然资源公司总部位于美国得克萨斯州欧文市，主要从事油气勘探业务，运营覆盖二叠纪盆地Spraberry产区的克莱恩页岩区块，是该区域最大的土地权益持有方，2024年5月被埃克森美孚收购。
EXAS vs PR — 直观对比
营收规模更大
PR
是对方的1.3倍
$878.4M
营收增速更快
EXAS
高出32.9%
-9.8%
净利率更高
PR
高出38.8%
-9.8%
两年增速更快
EXAS
近两年复合增速
-3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.2B |
| 净利润 | $-86.0M | $339.5M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 23.1% |
| 净利率 | -9.8% | 29.0% |
| 营收同比 | 23.1% | -9.8% |
| 净利润同比 | 90.1% | 56.7% |
| 每股收益（稀释后） | $-0.45 | $0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASPR
| Q4 25 | $878.4M | $1.2B | ||
| Q3 25 | $850.7M | $1.3B | ||
| Q2 25 | $811.1M | $1.2B | ||
| Q1 25 | $706.8M | $1.4B | ||
| Q4 24 | $713.4M | $1.3B | ||
| Q3 24 | $708.7M | $1.2B | ||
| Q2 24 | $699.3M | $1.2B | ||
| Q1 24 | $637.5M | $1.2B |
净利润EXASPR
| Q4 25 | $-86.0M | $339.5M | ||
| Q3 25 | $-19.6M | $59.2M | ||
| Q2 25 | $-1.2M | $207.1M | ||
| Q1 25 | $-101.2M | $329.3M | ||
| Q4 24 | $-864.6M | $216.7M | ||
| Q3 24 | $-38.2M | $386.4M | ||
| Q2 24 | $-15.8M | $235.1M | ||
| Q1 24 | $-110.2M | $146.6M |
毛利率EXASPR
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASPR
| Q4 25 | -9.4% | 23.1% | ||
| Q3 25 | -3.0% | 29.6% | ||
| Q2 25 | -0.3% | 24.8% | ||
| Q1 25 | -13.6% | 36.6% | ||
| Q4 24 | -122.8% | 32.8% | ||
| Q3 24 | -5.6% | 32.5% | ||
| Q2 24 | -3.8% | 36.5% | ||
| Q1 24 | -16.7% | 37.7% |
净利率EXASPR
| Q4 25 | -9.8% | 29.0% | ||
| Q3 25 | -2.3% | 4.5% | ||
| Q2 25 | -0.1% | 17.3% | ||
| Q1 25 | -14.3% | 23.9% | ||
| Q4 24 | -121.2% | 16.7% | ||
| Q3 24 | -5.4% | 31.8% | ||
| Q2 24 | -2.3% | 18.9% | ||
| Q1 24 | -17.3% | 11.8% |
每股收益（稀释后）EXASPR
| Q4 25 | $-0.45 | $0.48 | ||
| Q3 25 | $-0.10 | $0.08 | ||
| Q2 25 | $-0.01 | $0.28 | ||
| Q1 25 | $-0.54 | $0.44 | ||
| Q4 24 | $-4.69 | $0.31 | ||
| Q3 24 | $-0.21 | $0.53 | ||
| Q2 24 | $-0.09 | $0.36 | ||
| Q1 24 | $-0.60 | $0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $153.7M |
| 总债务越低越好 | — | $3.5B |
| 股东权益账面价值 | $2.4B | $10.3B |
| 总资产 | $5.9B | $17.9B |
| 负债/权益比越低杠杆越低 | — | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资EXASPR
| Q4 25 | $964.7M | $153.7M | ||
| Q3 25 | $1.0B | $111.8M | ||
| Q2 25 | $858.4M | $451.0M | ||
| Q1 25 | $786.2M | $702.2M | ||
| Q4 24 | $1.0B | $479.3M | ||
| Q3 24 | $1.0B | $272.0M | ||
| Q2 24 | $946.8M | $47.8M | ||
| Q1 24 | $652.1M | $12.7M |
总债务EXASPR
| Q4 25 | — | $3.5B | ||
| Q3 25 | — | $3.5B | ||
| Q2 25 | — | $4.0B | ||
| Q1 25 | — | $4.0B | ||
| Q4 24 | — | $4.2B | ||
| Q3 24 | — | $4.2B | ||
| Q2 24 | — | $3.9B | ||
| Q1 24 | — | $3.9B |
股东权益EXASPR
| Q4 25 | $2.4B | $10.3B | ||
| Q3 25 | $2.5B | $10.0B | ||
| Q2 25 | $2.5B | $9.5B | ||
| Q1 25 | $2.4B | $9.4B | ||
| Q4 24 | $2.4B | $9.1B | ||
| Q3 24 | $3.2B | $9.0B | ||
| Q2 24 | $3.2B | $8.3B | ||
| Q1 24 | $3.1B | $7.0B |
总资产EXASPR
| Q4 25 | $5.9B | $17.9B | ||
| Q3 25 | $5.9B | $17.3B | ||
| Q2 25 | $5.8B | $17.5B | ||
| Q1 25 | $5.7B | $17.1B | ||
| Q4 24 | $5.9B | $16.9B | ||
| Q3 24 | $6.7B | $16.6B | ||
| Q2 24 | $6.7B | $15.4B | ||
| Q1 24 | $6.4B | $15.1B |
负债/权益比EXASPR
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.42× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.46× | ||
| Q1 24 | — | 0.56× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $904.3M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 2.66× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASPR
| Q4 25 | $151.7M | $904.3M | ||
| Q3 25 | $219.9M | $766.5M | ||
| Q2 25 | $89.0M | $1.0B | ||
| Q1 25 | $30.8M | $898.0M | ||
| Q4 24 | $47.1M | $871.6M | ||
| Q3 24 | $138.7M | $954.4M | ||
| Q2 24 | $107.1M | $938.4M | ||
| Q1 24 | $-82.3M | $647.6M |
自由现金流EXASPR
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASPR
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASPR
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASPR
| Q4 25 | — | 2.66× | ||
| Q3 25 | — | 12.94× | ||
| Q2 25 | — | 5.01× | ||
| Q1 25 | — | 2.73× | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 2.47× | ||
| Q2 24 | — | 3.99× | ||
| Q1 24 | — | 4.42× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PR
| Crude Oil | $1.0B | 87% |
| Natural Gas Liquids Reserves | $145.1M | 12% |
